當(dāng)前位置：
Human Anti-Cardiolipin IgG ELISA kit 心磷脂IgG檢測(cè)試劑盒說(shuō)明書(shū)
發(fā)布時(shí)間：2023/11/8
點(diǎn)擊次數(shù)：411
人抗心磷脂IgG檢測(cè)試劑盒
Human Anti Cardiolipin IgG ELISA kit
cat#3300-170-CLG
Intended Use
Anti Cardiolipin IgG is an indirect enzyme immunoassay (ELISA) for thedetermination of IgG class autoantibodies against Cardiolipin in human serum orplasma. ADI’s Anti-Cardiolipin IgG ELISA KIT is intended for research use only,not for use in diagnostic procedures.
General Information
Anti-cardiolipin antibodies (aCL) can be considered as one of three groups ofanti-phospholipid antibodies, the others being VDRL and lupus anticoagulant(LAC). aCL and LAC antibodies appear to be closely related, or to recognizesimilar antigenic determinants. Of the anti-phospholipid antibodies, aCL areobserved most frequently and can be associated with a diverse set of clinicalmanifestations including neurological dysfunction, venous or arterial thrombosis,thrombocytopaenia and recurrent foetal loss5. Measuring aCL antibody levelsmay well be more useful than other anti-phospholipids because of these clinicalassociations6,7. The IgG isotype appears to provide the best correlation, IgM isalso found but IgA is more rare.
General Information
Anti-cardiolipin antibodies (aCL) can be considered as one of three groups ofanti-phospholipid antibodies, the others being VDRL and lupus anticoagulant(LAC). aCL and LAC antibodies appear to be closely related, or to recognizesimilar antigenic determinants. Of the anti-phospholipid antibodies, aCL areobserved most frequently and can be associated with a diverse set of clinicalmanifestations including neurological dysfunction, venous or arterial thrombosis,thrombocytopaenia and recurrent foetal loss5. Measuring aCL antibody levelsmay well be more useful than other anti-phospholipids because of these clinicalassociations6,7. The IgG isotype appears to provide the best correlation, IgM isalso found but IgA is more rare.
Measuring range
0 - 120 GPL-U/ml
Interferences:
No interference has been observed with haemolytic (up to 1000 mg/dl) or lipemic(up to 3 g/dl triglycerides) sera or plasma, or bilirubin (up to 40 mg/dl) containingsera or plasma. Nor have any interfering effects been observed with the use ofanticoagulants (Citrate, EDTA, Heparine). However for practical reasons it isrecommended that grossly hemolyzed or lipemic samples should be avoided.
